Recommendations for the selective use of herpes simplex virus type 2 serological tests

Clinical Infectious Diseases

Volumn 40, Issue 1, 2005, Pages 38-45

  Guerry, Sarah L ^a,d,f   Bauer, Heidi M ^a   Klausner, Jeffrey D ^b   Branagan, Barbara ^c,d   Kerndt, Peter R ^d   Allen, Barbara G ^e   Bolan, Gail ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b San Francisco Department of Health   (United States)

^c Humane Society of Sonoma County Animal Hospital   (United States)

^d LOS ANGELES COUNTY DEPARTMENT OF PUBLIC HEALTH   (United States)

^e Alameda County Public Health Department   (United States)

^f Los Angeles County STD Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

ADULT; CHILD; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; NEWBORN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SERODIAGNOSIS; SEROLOGY; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SYSTEMATIC REVIEW;

FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MICROBIOLOGICAL TECHNIQUES; SEROLOGIC TESTS;

EID: 11144246254     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426438     Document Type: Review

References (64)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
2. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-50.
3. Corey L, Handsfield HH. Genital herpes and public health: addressing a global problem. JAMA 2000; 283:791-4.
4. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 2002;35:S173-82.
5. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51(RR-6):1-78.
6. Mindel A, Taylor J. Debate: the argument against. Should every STD clinic patient be considered for type-specific serological screening for HSV? Herpes 2002; 9:35-7.
7. Brugha R, Brown D, Meheus A, Renton A. Should we be screening for asymptomatic HSV infections? Sex Transm Infect 1999; 75:142-4.
8. Ashley RL. Sorting out the new HSV type specific antibody tests. Sex Transm Infect 2001; 77:232-7.
9. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
10. ACOG practice bulletin. Management of herpes in pregnancy. Number 8 October 1999. Clinical Management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000; 68:165-73.
11. California STD Controllers Association and California Coalition of Local AIDS Directors. Guidance for STD clinical preventive services for persons infected with HIV. Sex Transm Dis 2001; 28:460-3.
12. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359:881-4.
13. Guerry S, Bauer H, Klausner J, et al. Guidelines for the use of herpes simplex virus (HSV) type 2 serologies: recommendations from the California Sexually Transmitted Disease (STD) Controllers Association and the California Department of Health Services (CA DHS). Berkelely, CA, 2003. Available at: http://www.stdhivtraining.org/cfm/resources.cfm#Guidelines. Accessed 2 April 2004.
14. Wallace RB. Screening for early and asymptomatic conditions. In: Wallace RB, Doebbeling BN, eds. Public health and preventative medicine. 14th ed. Stamford, CT: Appleton & Lange, 1998:907-9.
15. Cowan FM. Testing for type-specific antibody to herpes simplex virus-implications for clinical practice. J Antimicrob Chemother 2000; 45(Suppl T3):9-13.
16. Cusini M, Ghislanzoni M. The importance of diagnosing genital herpes. J Antimicrob Chemother 2001; 47(Suppl T1):9-16.
17. Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999; 12:1-8.
18. Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310-4.
19. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996; 100:27-32.
20. Catotti DN, Clarke P, Catoe KE. Herpes revisited: still a cause of concern. Sex Transm Dis 1993; 20:77-80.
21. Smith A, Denham I, Keogh L, et al. Psychosocial impact of type-specific herpes simplex serological testing on asymptomatic sexual health clinic attendees. Int J STD AIDS 2000; 11:15-20.
22. Turner K, Miyai T, Kent C, Klausner J. The psychosocial impact of testing individuals with no prior history of genital herpes for herpes simplex virus type 2. Sex Transm Dis 2004; 31:517-21.
23. Van Berkel C. A psychoeducational program increased knowledge and decreased sexual risk behaviors in young adults with genital herpes. West J Med 2000; 172:246.
24. Wald A, Corey L. Genital herpes. In: Holmes KK, Mardh P, Sparling PF, eds. Sexually transmitted diseases. 3 ed. New York: McGraw-Hill, 1999:285-312.
25. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
26. Turner KR, McFarland W, Kellogg TA, et al. Incidence and prevalence of herpes simplex virus type 2 infection in persons seeking repeat HIV counseling and testing. Sex Transm Dis 2003; 30:331-4.
27. Gottlieb S, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counselling. J Infect Dis 2004; 190:1059-67.
28. Shain RN, Piper JM, Newton ER, et al. A randomized, controlled trial of a behavioral intervention to prevent sexually transmitted disease among minority women. N Engl J Med 1999; 340:93-100.
29. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998; 280:1161-7.
30. Imrie J, Stephenson JM, Cowan FM, et al. A cognitive behavioural intervention to reduce sexually transmitted infections among gay men: randomised trial. BMJ 2001; 322:1451-6.
31. Dilley JW, Woods WJ, Sabatino J, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. J Acquir Immune Defic Syndr 2002; 30:177-86.
32. Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001; 285:3100-6.
33. Wald A, Langenberg A, Kexel E, Izu A, Ashley R, Corey L. Condoms protect men and women against herpes simplex virus type 2 acquisition [abstract B9E]. In: Proceedings of the 2002 National STD Prevention Conference (San Diego). Atlanta: Centers for Disease Control and Prevention 2002.
34. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997; 99:1092-7.
35. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
36. Hook EW III, Cannon RO, Nahmias AJ, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992; 165:251-5.
37. Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001; 8:46-9.
38. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280:61-6.
39. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-22.
40. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-25.
41. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766-70.
42. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
43. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21-8.
44. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-59.
45. McFarland W, Gwanzura L, Bassett MT, et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 1999; 180:1459-65.
46. Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JA. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect 1999; 75:98-102.
47. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432-8.
48. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
49. Gutierrez KM, Falkovitz Halpern MS, Maldonado Y, Arvin AM. The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. J Infect Dis 1999; 180:199-202.
50. Whitley RJ. Neonatal herpes simplex virus infections. J Med Virol 1993; (Suppl 1):13-21.
51. Sullivan-Bolyai J, Hull HF, Wilson C, Corey L. Neonatal herpes simplex virus infection in King County, Washington: increasing incidence and epidemiologic correlates. JAMA 1983; 250:3059-62.
52. Riley LE. Herpes simplex virus. Semin Perinatol 1998; 22:284-92.
53. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis 1988; 158:109-16.
54. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203-9.
55. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-15.
56. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med 1987; 316:240-4.
57. Randolph AG, Washington AE, Prober CG. Cesarean delivery for women presenting with genital herpes lesions: efficacy, risks, and costs. JAMA 1993; 270:77-82.
58. Kulhanjian JA, Soroush V, Au DS, et al. Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med 1992; 326:916-20.
59. Stone KM, Brooks CA, Guinan ME, Alexander ER. National surveillance for neonatal herpes simplex virus infections. Sex Transm Dis 1989; 16:152-6.
60. Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998; 105:275-80.
61. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996; 87:69-73.
62. Reiff-Eldridge R, Heffner C, Ephross S, Tennis P, White A, Andrews E. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical commitment. Am J Obstet Gynecol 2000; 182:159-63.
63. Marrazzo J, John G, Krohn M, Corey L. Cesarean delivery in women with genital herpes in Washington State, 1989-1991. Infect Dis Obstet Gynecol 1997; 5:29-35.
64. Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000; 183:400-6.